AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24382614 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 100% lavender oil (3 mL in a glass jar at bedside from 10 pm to 6 am)
Number of subjects: 50
Study 24382614 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 100% lavender oil
Number of subjects: 50
Study 24382614 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study 22239862 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily
Number of subjects: 1581
Study 22239862 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 50 mg twice daily
Number of subjects: 1581
Study 22239862 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 25 mg twice daily
Number of subjects: 1581
Study 22239862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1581
Study 19207432 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using indocyanine green (ICG) dye with a diode laser
Number of subjects: 16
Study 17502777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular biperiden
Number of subjects: 30
Study 17502777 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 30
Study 14982808 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole formulations with arachis oil‐polysorbate 80
Number of subjects: 0
Study 14982808 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole formulations with hydroxypropyl‐beta‐cyclodextrin
Number of subjects: 0
Study 14982808 — intervention group
Group type: COMPARATOR
Intervention: Macrogol suppositories
Number of subjects: 0
Study 12466924 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary task with varying S-R compatibility
Number of subjects: 0
Study 12466924 — intervention group
Group type: COMPARATOR
Intervention: Extra memory task (Experiment 1)
Number of subjects: 0
Study 12466924 — intervention group
Group type: COMPARATOR
Intervention: Increasing number of S-R alternatives in primary task (Experiment 2)
Number of subjects: 0
Study 12466924 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistency of previously used S-R mappings (Experiment 4)
Number of subjects: 0
Study 9655655 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 135
Study 9655655 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 135
Study 8587078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (3 g/day)
Number of subjects: 24
Study 8587078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2568327 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine nightly
Number of subjects: 242
Study 2568327 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 X 150 mg nizatidine daily
Number of subjects: 242
Study 2568327 — intervention group
Group type: COMPARATOR
Intervention: 2 X 150 mg ranitidine daily
Number of subjects: 242
Study 59013 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised maternal plasma-urate concentrations
Number of subjects: 332
Study 59013 — intervention group
Group type: COMPARATOR
Intervention: Maternal hypertension without hyperuricaemia
Number of subjects: 332
Study 59013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild maternal hypertension with severe hyperuricaemia
Number of subjects: 332
Study 59013 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-urate measurements
Number of subjects: 332
Study 31226388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent liver function testing (iLFT)
Number of subjects: 554
Study 31226388 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 554
Study 28096535 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline single-nucleotide polymorphisms (SNPs) associated with relapse
Number of subjects: 2225
Study 28096535 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline SNPs associated with rapid drug clearance or drug resistance
Number of subjects: 2225
Study 28096535 — intervention group
Group type: COMPARATOR
Intervention: Model without SNPs for black ancestry
Number of subjects: 2225
Study 28096535 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with SNPs for black ancestry
Number of subjects: 2225
Study 28096535 — intervention group
Group type: COMPARATOR
Intervention: Model without SNPs for Hispanic ancestry
Number of subjects: 2225
Study 28096535 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with SNPs for Hispanic ancestry
Number of subjects: 2225
Study 28096535 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase resistance or allergy SNPs in treatment arms
Number of subjects: 2225
Study 24671237 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS-containing infant formula (0.44 g/dl of GOS)
Number of subjects: 365
Study 24671237 — intervention group
Group type: COMPARATOR
Intervention: Control formula without GOS
Number of subjects: 365
Study 23616564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation with background movement
Number of subjects: 0
Study 23616564 — intervention group
Group type: COMPARATOR
Intervention: Prism adaptation
Number of subjects: 0
Study 21988774 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Based Health Insurance scheme
Number of subjects: 0
Study 19249633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading, 10 mg maintenance)
Number of subjects: 3534
Study 19249633 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading, 75 mg maintenance)
Number of subjects: 3534
Study 17259812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 (approximately 5x10^10)
Number of subjects: 24
Study 17259812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15294376 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25mg per day for 6 months
Number of subjects: 28
Study 15294376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11108307 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF 5 microg/kg/day
Number of subjects: 33
Study 11108307 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF 10 microg/kg/day
Number of subjects: 33
Study 11108307 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF 25 microg/kg/day
Number of subjects: 33
Study 11108307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11108307 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (including placebo)
Number of subjects: 33
Study 11108307 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosages of PEG-rHuMGDF
Number of subjects: 33
Study 11108307 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 33
Study 9512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride hydrochlorothiazide (5/50 mg/d)
Number of subjects: 20
Study 9512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/d)
Number of subjects: 20
Study 9512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg/d)
Number of subjects: 20
Study 9512875 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d)
Number of subjects: 20
Study 8457046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (15 micrograms/min)
Number of subjects: 24
Study 8457046 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (150 micrograms/min)
Number of subjects: 24
Study 2429095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 10
Study 2429095 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 10
Study 2429095 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and atenolol
Number of subjects: 10
Study 2429095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29718967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline 400 mg alone
Number of subjects: 33
Study 29718967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline 400 mg plus Rifampin 600 mg
Number of subjects: 33
Study 29718967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline 400 mg plus Rifabutin 300 mg
Number of subjects: 33
Study 27236272 — intervention group
Group type: EXPERIMENTAL
Intervention: AKB‐9778 monotherapy: subcutaneous AKB‐9778 15 mg BID + monthly sham intraocular injections
Number of subjects: 144
Study 27236272 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy: subcutaneous AKB‐9778 15 mg BID + monthly 0.3 mg ranibizumab
Number of subjects: 144
Study 27236272 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy: subcutaneous placebo injections BID + monthly 0.3 mg ranibizumab
Number of subjects: 144
Study 25614407 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular catheter
Number of subjects: 50
Study 25614407 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular catheter
Number of subjects: 50
Study 24120712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg b.i.d. for 5 days)
Number of subjects: 1709
Study 21775146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day for the first 3 days, then 300 mg/day for a further 2 days
Number of subjects: 40
Study 21775146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21775146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 40
Study 18815953 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy (IPT)
Number of subjects: 0
Study 18815953 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 0
Study 16546843 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg/day for 2 weeks)
Number of subjects: 10
Study 16546843 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated hypertensive patients)
Number of subjects: 10
Study 16546843 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive subjects)
Number of subjects: 10
Study 12704402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet (27% of energy as protein, 45% as carbohydrate)
Number of subjects: 36
Study 12704402 — intervention group
Group type: COMPARATOR
Intervention: Lower-Protein (LP) diet (16% of energy as protein, 57% as carbohydrate)
Number of subjects: 36
Study 9878015 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination drug therapy with indinavir, zidovudine, and lamivudine
Number of subjects: 27
Study 9878015 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination drug therapy after either indinavir or zidovudine-lamivudine treatment
Number of subjects: 27
Study 9878015 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged indinavir-zidovudine-lamivudine treatment
Number of subjects: 27
Study 9878015 — intervention group
Group type: COMPARATOR
Intervention: Control group (zidovudine plus lamivudine or zidovudine alone)
Number of subjects: 27
Study 8529495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled insulin pen (NovoLet)
Number of subjects: 60
Study 8529495 — intervention group
Group type: COMPARATOR
Intervention: Conventional syringes
Number of subjects: 60
Study 1958856 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day
Number of subjects: 6105
Study 1958856 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6105
Study 6759062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 20 mg
Number of subjects: 34
Study 6759062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 34
Study 6759062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciramadol 40 mg
Number of subjects: 34
Study 30920975 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg/day
Number of subjects: 150
Study 30920975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day
Number of subjects: 150
Study 30920975 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU/day
Number of subjects: 150
Study 30920975 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle plus placebo
Number of subjects: 150
Study 27659294 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day until disease progression or unacceptable toxicity
Number of subjects: 102
Study 27659294 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 102
Study 25662553 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive chlorhexidine gel 0.2%
Number of subjects: 7
Study 25662553 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 7
Study 23115078 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Deficit (exercise group)
Number of subjects: 21
Study 23115078 — intervention group
Group type: COMPARATOR
Intervention: Control (non-exercising group)
Number of subjects: 21
Study 21946712 — intervention group
Group type: EXPERIMENTAL
Intervention: ZeroFly® insecticide incorporated plastic sheeting (deltamethrin 2.0 g/kg or 265 mg/m2)
Number of subjects: 250
Study 21946712 — intervention group
Group type: COMPARATOR
Intervention: Untreated plastic sheets (control)
Number of subjects: 250
Study 19536922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 10
Study 19536922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16754759 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Solutions intervention (24-week psychoeducational group focused on illness management)
Number of subjects: 71
Study 16754759 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 71
Study 15544683 — intervention group
Group type: EXPERIMENTAL
Intervention: Package (booklet and 15‐min video)
Number of subjects: 65
Study 15544683 — intervention group
Group type: COMPARATOR
Intervention: Control (booklet on living with cancer)
Number of subjects: 65
Study 11822998 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg four times daily for 10 days)
Number of subjects: 41
Study 11822998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11822998 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 41
Study 9661546 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg (maximal dose 25 mg)
Number of subjects: 130
Study 9661546 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 130
Study 7631610 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive BRS measurement
Number of subjects: 40
Study 7631610 — intervention group
Group type: COMPARATOR
Intervention: Invasive BRS measurement
Number of subjects: 40
Study 7631610 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive technique after phenylephrine injection
Number of subjects: 40
Study 7631610 — intervention group
Group type: COMPARATOR
Intervention: Invasive technique after phenylephrine injection
Number of subjects: 40
Study 7631610 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive BRS value < 4.0 ms/mm Hg
Number of subjects: 40
Study 2239887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic endoprosthesis
Number of subjects: 50
Study 2239887 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 50
Study 320832 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated, rapidly dissolving lithium carbonate tablets
Number of subjects: 27
Study 320832 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-slow-release lithium sulphate tablets
Number of subjects: 27
Study 320832 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release lithium sulphate tablets
Number of subjects: 27
Study 6182175 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 10 mg 3 times daily for 1 week followed by 60 mg mianserin daily for a second week
Number of subjects: 20
Study 6182175 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline 25 mg 3 times daily for 1 week followed by 150 mg amitriptyline daily for a second week
Number of subjects: 20
Study 6182175 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment for 14 days
Number of subjects: 20
Study 30581109 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Longitudinal Strain (GLS)
Number of subjects: 100
Study 30581109 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Circumferential Strain (GCS)
Number of subjects: 100
Study 30581109 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Radial Strain (GRS)
Number of subjects: 100
Study 28925034 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.14% dipotassium oxalate monohydrate-containing strip (self-applied)
Number of subjects: 60
Study 28925034 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.14% dipotassium oxalate monohydrate-containing strip (professionally applied)
Number of subjects: 60
Study 28925034 — intervention group
Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 60
Study 28925034 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.14% dipotassium oxalate monohydrate-containing strip (self-applied and professionally applied)
Number of subjects: 60
Study 26555871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine 4 mg orally 1 hour before surgery and twice daily during the first postoperative week
Number of subjects: 60
Study 26555871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 60
Study 26555871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24826894 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion policy (counts <10 × 10(9) /L)
Number of subjects: 0
Study 24826894 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study 22842177 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day Fungisome
Number of subjects: 65
Study 22842177 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day Fungisome
Number of subjects: 65
Study 22842177 — intervention group
Group type: COMPARATOR
Intervention: 1 mg/kg/day conventional amphotericin B
Number of subjects: 65
Study 20146627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine plus efavirenz (arm 1)
Number of subjects: 30
Study 20146627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine plus atazanavir-ritonavir (arm 2)
Number of subjects: 30
Study 20146627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine plus zidovudine-abacavir (arm 3)
Number of subjects: 30
Study 17650789 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiguan Decoction (YGD) plus NP protocol of chemotherapy
Number of subjects: 92
Study 17650789 — intervention group
Group type: COMPARATOR
Intervention: NP protocol of chemotherapy
Number of subjects: 92
Study 15691685 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 300
Study 15691685 — intervention group
Group type: COMPARATOR
Intervention: CABG with CPB
Number of subjects: 300
Study 11844942 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment programme with hypnosis
Number of subjects: 45
Study 11844942 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive treatment programme without hypnosis
Number of subjects: 45
Study 10825859 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental essential oil‐containing dentifrice
Number of subjects: 42
Study 10825859 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 42
Study 8703662 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 8
Study 8703662 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 8
Study 8703662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine plus terfenadine
Number of subjects: 8
Study 8703662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2313527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine gluconate irrigation
Number of subjects: 222
Study 2313527 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine rinse (positive control)
Number of subjects: 222
Study 2313527 — intervention group
Group type: COMPARATOR
Intervention: Water irrigation (irrigation control)
Number of subjects: 222
Study 2313527 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice (negative control)
Number of subjects: 222
Study 7444376 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of calciumacetylsalicylic acid
Number of subjects: 0
Study 7444376 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of calciumacetylsalicylic acid
Number of subjects: 0
Study 7444376 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of 100 mg of calciumacetylsalicylic acid at 12 h intervals
Number of subjects: 0
Study 7444376 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h 100 mg doses of calciumacetylsalicylic acid (equal to 80 mg of aspirin)
Number of subjects: 0
Study 29730601 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate endoscopy with haemostatic powder application within 2 hours of admission
Number of subjects: 86
Study 29730601 — intervention group
Group type: COMPARATOR
Intervention: Early elective endoscopy only (control group)
Number of subjects: 86
Study 29730601 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate powder application
Number of subjects: 86
Study 27828791 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg infusion for 10 minutes, followed by 2 mg/kg infusion for 15 minutes if needed)
Number of subjects: 123
Study 27828791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (infusion for 10 minutes, followed by placebo infusion for 15 minutes if needed)
Number of subjects: 123
Study 27828791 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 123
Study 27828791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 27828791 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant and Placebo
Number of subjects: 123
Study 25700947 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (500mg)
Number of subjects: 24
Study 25700947 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (1000mg)
Number of subjects: 24
Study 25700947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24